ClinicalTrials.gg
Not yet recruitingNCT07117383Updated Dec 12, 2025

Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

A Phase 1 interventional study of ASP-001.1 and ASP-001 in Erectile Dysfunction, sponsored by Aspargo Labs, Inc. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Aspargo Labs, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 180 studies in Erectile Dysfunction with a site in United States — 26 open to participants now, 31 under way, 3 of them phase 3. Erectile Dysfunction · United States.

Planned enrollment
84th of 164
72 · median 75
Started
2026
with 6 others
Phase 1
20 of 180
3 open now
Primary completion
2026-03
later than 6 of 30 live
Registered
176th of 180
by date

Among the 180 studies in Erectile Dysfunction with a site in United States, this one is the 84th largest by planned enrollment of the 164 interventional ones that give a count, is one of 7 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 6 of the 30 other live ones, and was the 176th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

26 of the 180 studies in Erectile Dysfunction with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Erectile Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare how different sildenafil formulations are absorbed and tolerated in healthy adult males under fed conditions. The main questions it aims to answer are:

Do Hezkue and Hezkue Turbo differ in absorption compared to other commercial sildenafil products?

Are there any differences in safety or tolerability between the products?

Researchers will compare multiple formulations to evaluate differences in drug absorption and side effects.

Read the detailed description

The goal of this clinical trial is to learn how different formulations of sildenafil-used to treat erectile dysfunction-are absorbed in the body when taken with food, and to understand how safe and well-tolerated they are in healthy adult males. The main questions it aims to answer are:

How do the blood levels of sildenafil compare between Hezkue, Hezkue Turbo, and other commercial sildenafil products?

Do differences in formulation (such as particle size or combination with tadalafil) affect the absorption or safety profile?

Researchers will compare Hezkue and Hezkue Turbo to other sildenafil-containing products (such as Pfizer Viagra, BlueChew, and Ro Sparks) to see if there are differences in how quickly and how much of the drug enters the bloodstream.

Participants will:

  • Take a single oral dose of one of the test products after eating a high-fat meal.
  • Have blood samples taken over a 4-hour period to measure drug levels.
  • Be monitored for side effects and overall health for up to 4 days after each dose.
  • Have the option to return for additional visits to test other products, with a 4-day break in between.
03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • erectile dysfunction
  • Viagra
  • sildenafil
  • tadalafil
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be informed of the nature of the study and voluntarily agree to participate by signing an form prior to any study-specific procedures.
  • Participant must be a healthy male, aged 18 to 70 years (inclusive) at the time of dosing.
  • Participant must be judged by the Investigator or designee to be in good general health, as documented by medical history, physical examination, clinical laboratory tests, vital signs, and 12-lead (ECG). Any deviations from normal ranges must be assessed and deemed not by the Investigator or designee.
  • Participant must have a (CrCl) value greater than 80 mL/min, as calculated by the Cockcroft-Gault equation.
  • Participant must agree to practice an acceptable method of throughout the clinical trial, as outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to comply with study procedures.
  • Use of any drug (except Hezkue/Hezkue Turbo) within 30 days prior to dosing.
  • History of significant renal, hepatic, cardiovascular (including orthostatic hypotension), psychiatric, neoplastic, infectious disease, or diabetes mellitus.
  • abnormal lab results, vital signs, or ECGs.
  • Any hepatic impairment or abnormal liver function tests.
  • Positive test for surface antigen, antibody, or antibody.
  • Clinically significant illness within 28 days prior to dosing.
  • Known to sildenafil, tadalafil, vardenafil, or any component of the investigational product (e.g., peppermint oil).
  • History of significant food or drug allergies.
  • History of drug abuse within the past year or positive drug screen at screening.
  • Regular alcohol consumption exceeding 15 units per week.
  • Use of CYP450 enzyme inhibitors within 14 days prior to dosing.
  • Use of CYP450 enzyme inducers or St. John's Wort within 28 days prior to dosing.
  • Blood donation or significant blood loss within 3 months before screening.
  • Plasma donation within 14 days prior to first dose.
  • Inadequate venous access for repeated blood sampling.
  • Difficulty fasting or inability to consume standardized meals.
  • Intolerance to fatty foods or inability to consume a high-fat, high-calorie breakfast.
  • Difficulty swallowing.
  • Regular use of tobacco or nicotine products within 4 weeks prior to screening.
  • Major surgery within 3 months or minor surgery within 1 month before screening.
  • Considered unsuitable for study participation by the Investigator.
  • Institutionalized status.
  • Use of hormone replacement therapy within 6 months prior to dosing.
  • Consumption of Seville oranges, grapefruit, or pomelo within 7 days prior to dosing.
  • Consumption of caffeine, xanthine-containing products, or poppy seeds within 48 hours prior to dosing.
  • Receipt of a COVID-19 vaccine within 3 days prior to dosing.
  • Presence of braces, retainers, dentures, partial dentures, or tongue piercings.
  • Use of nitric oxide donors, organic nitrates/nitrites, antihypertensive medications, or PDE5 inhibitors within 14 days of dosing.
  • Blood pressure or heart rate outside acceptable ranges:

    • Systolic BP \<90 or >140 mmHg
    • Diastolic BP \<50 or >90 mmHg
    • Heart rate \<50 or >100 bpm
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Hezkue Formulations

    Participants in this arm receive a single dose of 100mg (miligrams) of either Hezkue® (ASP-001) or Hezkue Turbo® (ASP-001.1), both liquid formulations containing sildenafil citrate.

    Device: ASP-001.1 · Drug: ASP-001

  • Experimental
    Commercially Available Sildenafil Products

    Participants in this arm receive a single dose of one of several comparator products, including commercially available sildenafil tablets or sildenafil + tadalafil combination chewables.

    Drug: Commercial Sildenafil and Sildenafil/Tadalafil Products

Interventions

  • DeviceASP-001.1

    Bottle/pump containing ASP-001.1 suspension

    Also known as: Hezkue®, sildenafil citrate oral suspension, sildenafil

  • DrugASP-001

    Oral liquid suspension of sildenafil

    Also known as: Hezkue Turbo®, sildenafil citrate oral suspension, sildenafil

  • DrugCommercial Sildenafil and Sildenafil/Tadalafil Products

    A selection of marketed sildenafil or sildenafil + tadalafil products used as comparators. Includes tablets and chewables such as Viagra®, Galotam, BlueChew, Aristo Sildaristo, Lemonaid Viagra, Ro Sparks, Hims Hard Mints, and Hello Cake ED Cake Meds.

    Also known as: Viagra®, Galotam, BlueChew, Aristo Sildaristo, Lemonaid Viagra, Ro Sparks, Hims Hard Mints, Hello Cake ED Cake Meds

06

What researchers measure

Primary outcomes

  1. Tmax - Time to Maximum Observed Plasma Concentration of Sildenafil

    Measurement of the time (Tmax) to reach maximum observed plasma concentration of sildenafil following a single oral dose under fed conditions.

    Time frame: Baseline and up to 4 hours post-dose at 23 specified timepoints

  2. Cmax - Maximum Observed Plasma Concentration of Sildenafil

    Measurement of the maximum observed plasma concentration (Cmax) of sildenafil following a single oral dose of study drug.

    Time frame: Baseline and at 23 timepoints within 4 hours post-dose.

Secondary outcomes

  1. Number of Participants Reporting Oral Irritation, Dizziness, or Headache

    To assess the frequency and severity of oral irritation, dizziness, or headache following administration of ASP-001.1 (Hezkue Turbo). Descriptive summaries (mean, standard deviation, median, minimum, and maximum) of actual values and changes from baseline will be provided.

    Time frame: From pre-dose through 96 hours post-dose.

  2. Number of Participants With Adverse Events

    The frequency and type of adverse events reported during the study will be summarized, including severity and relationship to study drug.

    Time frame: From pre-dose through 96 hours post-dose.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because this study is an early-phase pharmacokinetic trial with a small sample size and limited potential for secondary analyses.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Mar 2026, 2 months later.

Of 18 phase 1 interventional studies under Erectile Dysfunction, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 19. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 12, 2025
StartEst.
Jan 2026
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07117383
Lead sponsor
Aspargo Labs, Inc
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Jan 2026 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Dec 12, 2025

Study contacts

Mario Guralnik, PhD
principal investigator · Aspargo Labs, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion